let's spell out the dollars and cents!

Daiichi Sankyo earned 8.7bn in revenue from Inavir (LANI) in the last quarter. This equates to approx $AUS108m.

Their manufacturing costs are approx 30% and royalties to Biota are what - approx 4%?

So DS nets the equivalent of around $AUS70m in one quarter.

Now, turn it all around. When Biota takes LANI to ROW, imagine the first global combined stockpile sales. We'd have to be looking at netting some hundreds of millions of dollars, which is more than our current market cap.

ONCE MORE FOR THE DUMMIES:

BLOCKBUSTER!

My investment in Biota is still medium term, but I'll be interested in cashing in if the price is right, if as Muzza speculates, buyers start circling - but the price must be right.